EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ -- AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac ...
Scientists at the Leibniz Institute of Photonic Technology (Leibniz IPHT) have developed a new microarray-based diagnostic ...
The MosaiQ solution is a next-generation IVD solution for autoimmune diseases, allergies and beyond. The multiplexed, fully automated planar microarray platform enables syndromic testing for complex ...
All reagents and multiplex microarray magazines are equipped with RFID tags to save time while avoiding manual errors. Unique combination of tests The MosaiQ AiPlex CTDplus assay enables a syndromic ...
EYSINS, Switzerland, Feb. 3, 2025 /PRNewswire/ -- AliveDx announces the receipt of IVDR-CE mark for its MosaiQ AiPlex ® CTDplus multiplex assay. The multiplex assay enables a syndromic approach, ...
Today, the number of functional as well as analytical protein microarray platforms which are based on protein probes, microarray adapted by molecular design, are still very few. The route adopted by ...
Philadelphia, PA, April 10, 2014 – Scientists in France have designed a new system for molecular blood group typing that offers blood banks the possibility of extensive screening of blood donors at a ...
Analysis of gene expression is critical to understanding the molecular underpinnings of normal and disease processes. Although in recent years the field has been flooded with microarray data, a ...
MosaiQ Assays* The MosaiQ system has the potential to offer a flexible menu of multiplex assays for autoimmune diseases and allergies, designed with key markers as per recommended clinical guidelines ...
Expert Rev Proteomics. 2013;10(5):417-420. Unlocking the proteome and delivering biomarkers to the clinic will be critical for early and improved diagnosis and prognosis. Conventional protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback